UK patients enabled access to transformative new medicines in shortest time possible via new, integrated Innovative Licensing and Access Pathway 

It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stag…